Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer

Niranjan Awasthi, Amanda Kirane, Margaret Schwarz, Jason E. Toombs, Rolf A. Brekken, Roderich E. Schwarz

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to conventional chemotherapy, in part due to the overexpression of inhibitors of apoptosis proteins (IAPs). Smac is an endogenous IAP-antagonist, which renders synthetic Smac mimetics attractive anticancer agents. We evaluated the benefits of combining a Smac mimetic, JP1201 (JP), with conventional chemotherapy agents used for PDAC management.Methods: Cell viability assays and protein expression analysis were performed using WST-1 reagent and Western blotting, respectively. Apoptosis was detected by annexin V/propidium iodide staining. In vivo tumor growth and survival studies were performed in murine PDAC xenografts.Results: JP and gemcitabine (Gem) inhibited PDAC cell proliferation with additive effects in combination. The percentage of early apoptotic cells in controls, JP, Gem and JP + Gem was 17%, 26%, 26% and 38%, respectively. JP-induced apoptosis was accompanied by PARP-1 cleavage. Similar additive anti-proliferative effects were seen for combinations of JP with doxorubicin (Dox) and docetaxel (DT). The JP + Gem combination caused a 30% decrease in tumor size in vivo compared to controls. Median animal survival was improved significantly in mice treated with JP + Gem (38 d) compared to controls (22 d), JP (28 d) or Gem (32 d) (p = 0.01). Animal survival was also improved with JP + DT treatment (32 d) compared to controls (16 d), JP (21 d) or DT alone (27 d).Conclusions: These results warrant further exploration of strategies that promote chemotherapy-induced apoptosis of tumors and highlight the potential of Smac mimetics in clinical PDAC therapy.

Original languageEnglish (US)
Article number15
JournalBMC Cancer
Volume11
DOIs
StatePublished - Jan 12 2011
Externally publishedYes

Fingerprint

gemcitabine
docetaxel
Pancreatic Neoplasms
Adenocarcinoma
Inhibitor of Apoptosis Proteins
Apoptosis
Drug Therapy
Neoplasms
Propidium
Annexin A5
Heterografts
Antineoplastic Agents
Doxorubicin
Cell Survival
Western Blotting
Cell Proliferation
Staining and Labeling

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. / Awasthi, Niranjan; Kirane, Amanda; Schwarz, Margaret; Toombs, Jason E.; Brekken, Rolf A.; Schwarz, Roderich E.

In: BMC Cancer, Vol. 11, 15, 12.01.2011.

Research output: Contribution to journalArticle

Awasthi, Niranjan ; Kirane, Amanda ; Schwarz, Margaret ; Toombs, Jason E. ; Brekken, Rolf A. ; Schwarz, Roderich E. / Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. In: BMC Cancer. 2011 ; Vol. 11.
@article{3063fe4316dc477080429d02b07b6a90,
title = "Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer",
abstract = "Background: Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to conventional chemotherapy, in part due to the overexpression of inhibitors of apoptosis proteins (IAPs). Smac is an endogenous IAP-antagonist, which renders synthetic Smac mimetics attractive anticancer agents. We evaluated the benefits of combining a Smac mimetic, JP1201 (JP), with conventional chemotherapy agents used for PDAC management.Methods: Cell viability assays and protein expression analysis were performed using WST-1 reagent and Western blotting, respectively. Apoptosis was detected by annexin V/propidium iodide staining. In vivo tumor growth and survival studies were performed in murine PDAC xenografts.Results: JP and gemcitabine (Gem) inhibited PDAC cell proliferation with additive effects in combination. The percentage of early apoptotic cells in controls, JP, Gem and JP + Gem was 17{\%}, 26{\%}, 26{\%} and 38{\%}, respectively. JP-induced apoptosis was accompanied by PARP-1 cleavage. Similar additive anti-proliferative effects were seen for combinations of JP with doxorubicin (Dox) and docetaxel (DT). The JP + Gem combination caused a 30{\%} decrease in tumor size in vivo compared to controls. Median animal survival was improved significantly in mice treated with JP + Gem (38 d) compared to controls (22 d), JP (28 d) or Gem (32 d) (p = 0.01). Animal survival was also improved with JP + DT treatment (32 d) compared to controls (16 d), JP (21 d) or DT alone (27 d).Conclusions: These results warrant further exploration of strategies that promote chemotherapy-induced apoptosis of tumors and highlight the potential of Smac mimetics in clinical PDAC therapy.",
author = "Niranjan Awasthi and Amanda Kirane and Margaret Schwarz and Toombs, {Jason E.} and Brekken, {Rolf A.} and Schwarz, {Roderich E.}",
year = "2011",
month = "1",
day = "12",
doi = "10.1186/1471-2407-11-15",
language = "English (US)",
volume = "11",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer

AU - Awasthi, Niranjan

AU - Kirane, Amanda

AU - Schwarz, Margaret

AU - Toombs, Jason E.

AU - Brekken, Rolf A.

AU - Schwarz, Roderich E.

PY - 2011/1/12

Y1 - 2011/1/12

N2 - Background: Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to conventional chemotherapy, in part due to the overexpression of inhibitors of apoptosis proteins (IAPs). Smac is an endogenous IAP-antagonist, which renders synthetic Smac mimetics attractive anticancer agents. We evaluated the benefits of combining a Smac mimetic, JP1201 (JP), with conventional chemotherapy agents used for PDAC management.Methods: Cell viability assays and protein expression analysis were performed using WST-1 reagent and Western blotting, respectively. Apoptosis was detected by annexin V/propidium iodide staining. In vivo tumor growth and survival studies were performed in murine PDAC xenografts.Results: JP and gemcitabine (Gem) inhibited PDAC cell proliferation with additive effects in combination. The percentage of early apoptotic cells in controls, JP, Gem and JP + Gem was 17%, 26%, 26% and 38%, respectively. JP-induced apoptosis was accompanied by PARP-1 cleavage. Similar additive anti-proliferative effects were seen for combinations of JP with doxorubicin (Dox) and docetaxel (DT). The JP + Gem combination caused a 30% decrease in tumor size in vivo compared to controls. Median animal survival was improved significantly in mice treated with JP + Gem (38 d) compared to controls (22 d), JP (28 d) or Gem (32 d) (p = 0.01). Animal survival was also improved with JP + DT treatment (32 d) compared to controls (16 d), JP (21 d) or DT alone (27 d).Conclusions: These results warrant further exploration of strategies that promote chemotherapy-induced apoptosis of tumors and highlight the potential of Smac mimetics in clinical PDAC therapy.

AB - Background: Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to conventional chemotherapy, in part due to the overexpression of inhibitors of apoptosis proteins (IAPs). Smac is an endogenous IAP-antagonist, which renders synthetic Smac mimetics attractive anticancer agents. We evaluated the benefits of combining a Smac mimetic, JP1201 (JP), with conventional chemotherapy agents used for PDAC management.Methods: Cell viability assays and protein expression analysis were performed using WST-1 reagent and Western blotting, respectively. Apoptosis was detected by annexin V/propidium iodide staining. In vivo tumor growth and survival studies were performed in murine PDAC xenografts.Results: JP and gemcitabine (Gem) inhibited PDAC cell proliferation with additive effects in combination. The percentage of early apoptotic cells in controls, JP, Gem and JP + Gem was 17%, 26%, 26% and 38%, respectively. JP-induced apoptosis was accompanied by PARP-1 cleavage. Similar additive anti-proliferative effects were seen for combinations of JP with doxorubicin (Dox) and docetaxel (DT). The JP + Gem combination caused a 30% decrease in tumor size in vivo compared to controls. Median animal survival was improved significantly in mice treated with JP + Gem (38 d) compared to controls (22 d), JP (28 d) or Gem (32 d) (p = 0.01). Animal survival was also improved with JP + DT treatment (32 d) compared to controls (16 d), JP (21 d) or DT alone (27 d).Conclusions: These results warrant further exploration of strategies that promote chemotherapy-induced apoptosis of tumors and highlight the potential of Smac mimetics in clinical PDAC therapy.

UR - http://www.scopus.com/inward/record.url?scp=78651239481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651239481&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-11-15

DO - 10.1186/1471-2407-11-15

M3 - Article

VL - 11

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 15

ER -